Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
This work is licensed under the Creative Commons Attribution 4.0 International License.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49. doi: 10.3322/caac.21660SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalAGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin2021712094910.3322/caac.21660Open DOISearch in Google Scholar
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 358–76. doi: 10.1016/j.annonc.2022.12.013HendriksLEKerrKMMenisJMokTSNestleUPassaroANon-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnn Oncol2023343587610.1016/j.annonc.2022.12.013Open DOISearch in Google Scholar
Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res 2020; 39: 204. doi: 10.1186/s13046-020-01709-5JiangXWangJDengXXiongFZhangSGongZThe role of microenvironment in tumor angiogenesisJ Exp Clin Cancer Res20203920410.1186/s13046-020-01709-5Open DOISearch in Google Scholar
Manzo A, Carillio G, Montanino A, Costanzo R, Sandomenico C, Rocco G, et al. Focus on nintedanib in NSCLC and other tumors. Front Med 2016; 3: 68. doi: 10.3389/fmed.2016.00068ManzoACarillioGMontaninoACostanzoRSandomenicoCRoccoGFocus on nintedanib in NSCLC and other tumorsFront Med201636810.3389/fmed.2016.00068Open DOISearch in Google Scholar
Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol 2017; 241: 362–74. doi: 10.1002/path.4845BridgemanVLVermeulenPBFooSBileczADaleyFKostarasEVessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis modelsJ Pathol20172413627410.1002/path.4845Open DOISearch in Google Scholar
Wang Y, Yang R, Wang X, Ci H, Zhou L, Zhu B, et al. Evaluation of the correlation of vasculogenic mimicry, Notch4, DLL4, and KAI1/CD82 in the prediction of metastasis and prognosis in non-small cell lung cancer. Medicine 2018; 97: e13817. doi: 10.1097/MD.0000000000013817WangYYangRWangXCiHZhouLZhuBEvaluation of the correlation of vasculogenic mimicry, Notch4, DLL4, and KAI1/CD82 in the prediction of metastasis and prognosis in non-small cell lung cancerMedicine201897e1381710.1097/MD.0000000000013817Open DOISearch in Google Scholar
Daum S, Hagen H, Naismith E, Wolf D, Pircher A. The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - New combinational approaches and strategies of neovessel inhibition. Front Cell Dev Biol 2021; 8: 610903. doi: 10.3389/fcell.2020.610903DaumSHagenHNaismithEWolfDPircherA.The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - New combinational approaches and strategies of neovessel inhibitionFront Cell Dev Biol2021861090310.3389/fcell.2020.610903Open DOISearch in Google Scholar
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50. doi: 10.1056/NEJMoa061884SandlerAGrayRPerryMCBrahmerJSchillerJHDowlatiAPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med200635525425010.1056/NEJMoa061884Open DOISearch in Google Scholar
Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143–55. doi: 10.1016/S1470-2045(13)70586-2ReckMKaiserRMellemgaardADouillardJYOrlovSKrzakowskiMLUME-Lung 1 Study GroupDocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol2014151435510.1016/S1470-2045(13)70586-2Open DOISearch in Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47. doi: 10.1016/j.ejca.2008.10.026EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer2009452284710.1016/j.ejca.2008.10.026Open DOISearch in Google Scholar
US National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (2009). [cited 2023 Apr 14]. Avaible at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htmUS National Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE) v4.02009[cited 2023 Apr 14]. Avaible at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htmSearch in Google Scholar
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078–92. doi: 10.1056/NEJMoa1801005GandhiLRodríguez-AbreuDGadgeelSEstebanEFelipEDe AngelisFPembrolizumab plus chemotherapy in metastatic non-small-cell lung cancerN Engl J Med201837820789210.1056/NEJMoa1801005Open DOISearch in Google Scholar
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami Net, al. IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288–301. doi: 10.1056/NEJMoa1716948SocinskiMAJotteRMCappuzzoFOrlandiFStroyakovskiyDNogamiNIMpower150 Study GroupAtezolizumab for first-line treatment of metastatic nonsquamous NSCLCN Engl J Med2018378228830110.1056/NEJMoa1716948Open DOISearch in Google Scholar
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924–37. doi: 10.1016/S1470-2045(19)30167-6WestHMcCleodMHusseinMMorabitoARittmeyerAConterHJAtezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialLancet Oncol2019209243710.1016/S1470-2045(19)30167-6Open DOISearch in Google Scholar
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665–73. doi: 10.1016/S0140-6736(14)60845-XGaronEBCiuleanuTEArrietaOPrabhashKSyrigosKNGokselTRamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet20143846657310.1016/S0140-6736(14)60845-XOpen DOISearch in Google Scholar
Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 Study. Target Oncol 2017; 12: 475–85. doi: 10.1007/s11523-017-0517-2GottfriedMBennounaJBondarenkoIDouillardJYHeigenerDFKrzakowskiMEfficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 StudyTarget Oncol2017124758510.1007/s11523-017-0517-2Open DOISearch in Google Scholar
Metzenmacher M, Rizzo F, Kambartel K, Panse J, Schaufler D, Scheffler M, et al. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. Future Oncol 2021; 17: 3965–76. doi: 10.2217/fon-2021-0424MetzenmacherMRizzoFKambartelKPanseJSchauflerDSchefflerMReal-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinomaFuture Oncol20211739657610.2217/fon-2021-0424Open DOISearch in Google Scholar
Grohé C, Blau W, Gleiber W, Haas S, Hammerschmidt S, Krüger S, et al. Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: Results from the ongoing, non-interventional VARGADO Study. Clin Oncol 2022; 34: 459–68. doi: 10.1016/j.clon.2021.12.010GrohéCBlauWGleiberWHaasSHammerschmidtSKrügerSReal-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: Results from the ongoing, non-interventional VARGADO StudyClin Oncol2022344596810.1016/j.clon.2021.12.010Open DOISearch in Google Scholar
Corral J, Majem M, Rodríguez-Abreu D, Carcereny E, Cortes ÁA, Llorente M, et al. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clin Transl Oncol 2019; 21: 1270–9. doi: 10.1007/s12094-019-02053-7CorralJMajemMRodríguez-AbreuDCarcerenyECortesÁALlorenteMEfficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU programClin Transl Oncol2019211270910.1007/s12094-019-02053-7Open DOISearch in Google Scholar
Riudavets M, Bosch-Barrera J, Cabezón-Gutiérrez L, Diz Taín P, Hernández A, Alonso M, et al. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clin Transl Oncol 2021; 23: 2560–7. doi: 10.1007/s12094-021-02661-2RiudavetsMBosch-BarreraJCabezón-GutiérrezLDiz TaínPHernándezAAlonsoMEfficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinomaClin Transl Oncol2021232560710.1007/s12094-021-02661-2Open DOISearch in Google Scholar
Hong SH, An HJ, Kim K, Lee SS, Lee YG, Yuh YJ, et al. Impact of epidermal growth factor receptor mutation on clinical outcomes of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer from the Korean Named Patient Program. Oncology 2019; 96: 51–8. doi: 10.1159/000492472HongSHAnHJKimKLeeSSLeeYGYuhYJImpact of epidermal growth factor receptor mutation on clinical outcomes of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer from the Korean Named Patient ProgramOncology20199651810.1159/000492472Open DOISearch in Google Scholar
Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011; 16: 1729–40. doi: 10.1634/theoncologist.2011-0163DienstmannRBrañaIRodonJTaberneroJ.Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsOncologist20111617294010.1634/theoncologist.2011-0163Open DOISearch in Google Scholar
Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28: 949–54. doi: 10.1200/JCO.2009DahlbergSESandlerABBrahmerJRSchillerJHJohnsonDH.Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599J Clin Oncol2010289495410.1200/JCO.2009Open DOISearch in Google Scholar